Amid the COVID-19 crisis, the United States human vaccines market is poised to grow by US$ 31,517 million by 2028, accelerating at a CAGR of 7% during the forecast period.
The prominent factors that are expected to contribute to the growth of the United States human vaccines market:
• Increased Disease Awareness
• Approval/launches of the New Vaccines
• Rising Focus on Immunization Programs
• Increasing Investments and Government Support for the Vaccines Development
After conducting thorough research on the historical and current growth parameters, the growth prospects of the United States human vaccines market are obtained with maximum precision.
This new 2022 market report provides a holistic analysis of the entire United States human vaccines market. The report offers the most up–to–date industry data on the actual market situation and future outlook for the United States’ human vaccines market. The report also provides up–to–date historical market size data for the period 2018 – 2021 and an illustrative forecast to 2028 covering key market aspects like market value, analysis, and trends for human vaccines in the United States. A comprehensive analysis has been done on market share with the percentage of all the 45 human vaccines brand used in the United States.
The report contains a deep analysis of the United States human vaccines market size in terms of value. The report provides a clear insight into current and future developments of the United States vaccines market. The report also explores the detailed analysis, insights of the top 45 vaccines market assessment in the United States from 2018 to 2021, and forecasts to 2028. The report also details the latest information about the vaccine’s pricing analysis, insights, and trends, and the regulatory framework of the United States human vaccines market.
The report also tracks and analyses competitive developments, including collaboration, partnership deals, distribution, exclusive and licensing agreements, new vaccine developments, and R&D activities in the market. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the market.
The report also analyses detailed profiles of innovative and leading players with information on business overview, companies’ vaccines portfolio, promising vaccines in the clinical development, and the newest developments
The report will serve as a source for a 360-degree analysis, thoroughly integrating different models.
This Newest and Comprehensive the United States Human Vaccines Market Research Report 2022 Delivers:
• Comprehensive Research Methodology of the United States Human Vaccines Market
• Detailed and Extensive Market Overview with Key Analyst Insights
• Insights about Market Determinants that are Stimulating the United States Human Vaccines Market
• To Analyze the Historical Growth in the Market Size of the United States Human Vaccines Market from 2018 to 2021
• To Estimate and Forecast the Market Size of the United States Human Vaccines Market from 2022 to 2028 and Growth Rate until 2028
• Detailed Insights of the Top 45 Human Vaccines Market Value Used in the U.S. with Six Years Forecast
• An Insightful Analysis of the Top 45 Vaccines Brand Market Share and Y-o-Y Growth Rate
• Delivers All-inclusive Insights on the Latest Pricing Analysis, Insights, and Trends
• Delivers an In-Depth Analysis of Evolving Market Trends, Drivers, and Restraints of the United States Human Vaccines Market
• An Insightful Investigation has been done on Promising Human Vaccines in the Clinical Development
• Delivers Comprehensive Insights into the Regulatory Framework of the United States Human Vaccines Market
• Tracks Competitive Developments, Approaches, Recent Industry Developments, Partnership, Collaboration Deals, Distribution, Exclusive, and Licensing Agreement
• A Comprehensive List of the Leading Companies along with the Analysis of their Current Vaccines Portfolio, Promising Human Vaccines in the Clinical Development, and Present Development
The Key Market Players for the United States Human Vaccines Market are Listed Below:
• Pfizer
• Merck
• Sanofi Pasteur
• Seqirus (CSL Limited)
• AstraZeneca
• GlaxoSmithKline (GSK)
• Emergent Biosolutions
• Dynavax Technologies Corporation
The Following 45 Leading Human Vaccines Brand are Detailed with Market Value and Six-Years Forecast:
1) Fluad
2) Trumenba
3) Deptacel
4) Quadracel
5) Kinrix
6) Pentacel
7) Vaxelis
8) IPOL
9) Vaqta
10) Havrix
11) Twinrix
12) Engerix
13) PedvaxHIB
14) ActHIB
15) Hiberix
16) MenQuadfi
17) Tenivac
18) Imovax
19) Prevnar 13
20) Gardasil 9
21) Menactra
22) Fluarix
23) FluLaval
24) Varivax
25) Proquad
26) M–M–R II
27) Adacel
28) Boostrix
29) Bexsero
30) Menveo
31) Shingrix
32) Rotateq
33) Rotarix
34) Infanrix
35) Pediarix
36) Heplisav–B
37) TDVAX
38) Biothrax
39) Recombivax HB
40) Pneumovax 23
41) FluMist Quadrivalent
42) Flucelvax Quadrivalent
43) Afluria Quadrivalent
44) Fluzone Quadrivalent
45) Flublok Quadrivalent
The Report Helps Answer the Following Questions:
• What is the current scenario of the United States human vaccines market?
• What is the total market size and forecast (until 2028) of the United States human vaccines market?
• How big is the United States human vaccines market?
• At what CAGR is the U.S. human vaccines market projected to grow in the forecast period (2022-2028)?
• What are the leading human vaccines? What are their revenue potentials to 2028?
• Which human vaccine brand provides the highest market share?
• What is the regulatory framework in the United States vaccines market?
• What are the key factors driving the United States human vaccines market?
• What are the key challenges of the United States human vaccines market?
• What are the major deals and agreement happenings in the United States human vaccines market?
• What are the United States human vaccines pricing trends and analysis?
• What are the various human vaccines available in the United States?
• Who are the topmost market players? What are their happenings, current developments, and scenarios?
• How is the market predicted to develop in the future?
'
1. Executive Summary
2. United States Human Vaccines Market Size and Forecast (2018 – 2028)
3. United States Human Vaccines Brand Market Share and Y–o–Y Growth (%), 2018 – 2028
4. Key Market Growth Drivers and Challenges in the United States Human Vaccines Market
4.1 Key Market Growth Drivers
4.2 Key Market Challenges
5. United States Top 45 Human Vaccines Market Value Analysis, Insights and Forecasts,2018 – 2028
5.1 Daptacel
5.2 Quadracel
5.3 Kinrix
5.4 Vaxelis
5.5 IPOL
5.6 Vaqta
5.7 Havrix
5.8 Twinrix
5.9 Engerix B
5.10 PedvaxHIB
5.11 ActHIB
5.12 Hiberix
5.13 MenQuadfi
5.14 Tenivac
5.15 Imovax
5.16 FluMist Quadrivalent
5.17 Prevnar 13
5.18 Gardasil 9
5.19 Fluzone Quadrivalent
5.20 Flublok
5.21 Flucelvax Quadrivalent
5.22 Afluria Quadrivalent
5.23 Fluad
5.24 Varivax
5.25 Menactra
5.26 Proquad
5.27 Pneumovax 23
5.28 Fluarix
5.29 FluLaval
5.30 M–M–R II
5.31 Adacel
5.32 Boostrix
5.33 Bexsero
5.34 Menveo
5.35 Trumenba
5.36 Shingrix
5.37 Pentacel
5.38 Recombivax HB
5.39 Rotateq
5.40 Rotarix
5.41 Pediarix
5.42 Infanrix
5.43 Heplisav–B
5.44 TDVAX
5.45 BioThrax
5.46 Other Vaccines
6. United States Human Vaccines Pricing Analysis, Insights and Trends
7. Regulatory Framework of the United States Human Vaccines Market
8. Major Deals and Agreement Happenings in the Human Vaccines Market
8.1 Merger & Acquisitions
8.2 Collaboration Deals
8.3 Licensing Agreement
8.4 Exclusive Agreement
8.5 Distribution Agreement
8.6 Partnership Deals
9. Leading Companies in the United States Human Vaccines Market
9.1 Sanofi Pasteur
9.1.1 Business Overview
9.1.2 Human Vaccines Portfolio
9.1.3 Promising Human Vaccines in the Clinical Development
9.1.4 Recent Development
9.2 GlaxoSmithKline (GSK)
9.2.1 Business Overview
9.2.2 Human Vaccines Portfolio
9.2.3 Promising Human Vaccines in the Clinical Development
9.2.4 Recent Development
9.3 Merck
9.3.1 Business Overview
9.3.2 Human Vaccines Portfolio
9.3.3 Promising Human Vaccines in the Clinical Development
9.3.4 Recent Development
9.4 Pfizer
9.4.1 Business Overview
9.4.2 Human Vaccines Portfolio
9.4.3 Promising Human Vaccines in the Clinical Development
9.4.4 Recent Development
9.5 Seqirus (CSL Limited)
9.5.1 Business Overview
9.5.2 Human Vaccines Portfolio
9.5.3 Promising Human Vaccines in the Clinical Development
9.5.4 Recent Development
9.6 AstraZeneca
9.6.1 Business Overview
9.6.2 Human Vaccines Portfolio
9.6.3 Promising Human Vaccines in the Clinical Development
9.6.4 Recent Development
9.7 Dynavax Technologies Corporation
9.7.1 Business Overview
9.7.2 Human Vaccines Portfolio
9.7.3 Promising Human Vaccines in the Clinical Development
9.7.4 Recent Development
9.8 Emergent BioSolutions Inc.
9.8.1 Business Overview
9.8.2 Human Vaccines Portfolio
9.8.3 Promising Human Vaccines in the Clinical Development
9.8.4 Recent Development
List of Tables
Table 3–1: United States Human Vaccines Brand Market Share & Y–o–Y Growth (Percent), 2018 – 2021
Table 3–2: United States Human Vaccines Brand Market Share & Y–o–Y Growth Forecast (Percent), 2022 – 2028
Table 6–1: United States Adult Vaccines Price, 2022 – 2023
Table 6–2: United States Adult Influenza Vaccines Price, 2022 – 2023
Table 6–3: United States Pediatric Vaccines Price, 2022 – 2023
Table 6–4: United States Pediatric Influenza Vaccines Price, 2022 – 2023
Table 7–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 8–1: Merger & Acquisitions in the Human Vaccines Market
Table 8–2: Collaboration Deals in the Human Vaccines Market
Table 8–3: Licensing Agreement in the Human Vaccines Market
Table 8–4: Exclusive Agreement in the Human Vaccines Market
Table 8–5: Distribution Agreement in the Human Vaccines Market
Table 8–6: Partnership Deals in the Human Vaccines Market
Table 9–1: Sanofi Promising Human Vaccines in the Clinical Development
Table 9–2: GSK Promising Human Vaccines in the Clinical Development
Table 9–3: Merck Promising Human Vaccines in the Clinical Development
Table 9–4: Pfizer Promising Human Vaccines in the Clinical Development
Table 9–5: Seqirus Promising Human Vaccines in the Clinical Development
Table 9–6: AstraZeneca Promising Human Vaccines in the Clinical Development
Table 9–7: Dynavax Technologies Corporation Promising Human Vaccines in the Clinical Development
Table 9–8: Emergent BioSolutions Inc. Promising Human Vaccines in the Clinical Development
List of Figures
Figure 2–1: United States Human Vaccines Market Size (Million US$),2018 – 2021
Figure 2–2: United States Human Vaccines Market Size Forecast (Million US$),2022 – 2028
Figure 5–1: United States Daptacel Market Value (Million US$),2018 – 2021
Figure 5–2: United States Daptacel Market Value Forecast (Million US$),2022 – 2028
Figure 5–3: United States Quadracel Market Value (Million US$),2018 – 2021
Figure 5–4: United States Quadracel Market Value Forecast (Million US$),2022 – 2028
Figure 5–5: United States Kinrix Market Value (Million US$),2018 – 2021
Figure 5–6: United States Kinrix Market Value Forecast (Million US$),2022 – 2028
Figure 5–7: United States Vaxelis Market Value (Million US$),2018 – 2021
Figure 5–8: United States Vaxelis Market Value Forecast (Million US$),2022 – 2028
Figure 5–9: United States IPOL Market Value (Million US$),2018 – 2021
Figure 5–10: United States IPOL Market Value Forecast (Million US$),2022 – 2028
Figure 5–11: United States Vaqta Market Value (Million US$),2018 – 2021
Figure 5–12: United States Vaqta Market Value Forecast (Million US$),2022 – 2028
Figure 5–13: United States Havrix Market Value (Million US$),2018 – 2021
Figure 5–14: United States Havrix Market Value Forecast (Million US$),2022 – 2028
Figure 5–15: United States Twinrix Market Value (Million US$),2018 – 2021
Figure 5–16: United States Twinrix Market Value Forecast (Million US$),2022 – 2028
Figure 5–17: United States Engerix B Market Value (Million US$),2018 – 2021
Figure 5–18: United States Engerix B Market Value Forecast (Million US$),2022 – 2028
Figure 5–19: United States PedvaxHIB Market Value (Million US$),2018 – 2021
Figure 5–20: United States PedvaxHIB Market Value Forecast (Million US$),2022 – 2028
Figure 5–21: United States ActHIB Market Value (Million US$),2018 – 2021
Figure 5–22: United States ActHIB Market Value Forecast (Million US$),2022 – 2028
Figure 5–23: United States Hiberix Market Value (Million US$),2018 – 2021
Figure 5–24: United States Hiberix Market Value Forecast (Million US$),2022 – 2028
Figure 5–25: United States MenQuadfi Market Value and Forecast (Million US$),2021 – 2028
Figure 5–26: United States Tenivac Market Value (Million US$),2018 – 2021
Figure 5–27: United States Tenivac Market Value Forecast (Million US$),2022 – 2028
Figure 5–28: United States Imovax Market Value (Million US$),2018 – 2021
Figure 5–29: United States Imovax Market Value Forecast (Million US$),2022 – 2028
Figure 5–30: United States FluMist Quadrivalent Market Value (Million US$),2018 – 2021
Figure 5–31: United States FluMist Quadrivalent Market Value Forecast (Million US$),2022 – 2028
Figure 5–32: United States Prevnar 13 Market Value (Million US$),2018 – 2021
Figure 5–33: United States Prevnar 13 Market Value Forecast (Million US$),2022 – 2028
Figure 5–34: United States Gardasil 9 Market Value (Million US$),2018 – 2021
Figure 5–35: United States Gardasil 9 Market Value Forecast (Million US$),2022 – 2028
Figure 5–36: United States Fluzone Market Value (Million US$),2018 – 2021
Figure 5–37: United States Fluzone Market Value Forecast (Million US$),2022 – 2028
Figure 5–38: United States Flublok Market Value (Million US$), 2018 – 2021
Figure 5–39: United States Flublok Market Value Forecast (Million US$), 2022 – 2028
Figure 5–40: United States Flucelvax Quadrivalent Market Value (Million US$),2018 – 2021
Figure 5–41: United States Flucelvax Quadrivalent Market Value Forecast (Million US$),2022 – 2028
Figure 5–42: United States Afluria Quadrivalent Market Value (Million US$),2018 – 2021
Figure 5–43: United States Afluria Quadrivalent Market Value Forecast (Million US$),2022 – 2028
Figure 5–44: United States Fluad Market Value (Million US$),2018 – 2021
Figure 5–45: United States Fluad Market Value Forecast (Million US$),2022 – 2028
Figure 5–46: United States Varivax Market Value (Million US$),2018 – 2021
Figure 5–47: United States Varivax Market Value Forecast (Million US$),2022 – 2028
Figure 5–48: United States Menactra Market Value (Million US$),2018 – 2021
Figure 5–49: United States Menactra Market Value Forecast (Million US$),2022 – 2028
Figure 5–50: United States Proquad Market Value (Million US$),2018 – 2021
Figure 5–51: United States Proquad Market Value Forecast (Million US$),2022 – 2028
Figure 5–52: United States Pneumovax 23 Market Value (Million US$),2018 – 2021
Figure 5–53: United States Pneumovax 23 Market Value Forecast (Million US$),2022 – 2028
Figure 5–54: United States Fluarix Market Value (Million US$),2018 – 2021
Figure 5–55: United States FluLaval Market Value Forecast (Million US$),2022 – 2028
Figure 5–56: United States FluLaval Market Value (Million US$),2018 – 2021
Figure 5–57: United States FluLaval Market Value Forecast (Million US$),2022 – 2028
Figure 5–58: United States M–M–R ll Market Value (Million US$),2018 – 2021
Figure 5–59: United States M–M–R ll Market Value Forecast (Million US$),2022 – 2028
Figure 5–60: United States Adacel Market Value (Million US$),2018 – 2021
Figure 5–61: United States Adacel Market Value Forecast (Million US$),2022 – 2028
Figure 5–62: United States Boostrix Market Value (Million US$),2018 – 2021
Figure 5–63: United States Boostrix Market Value Forecast (Million US$),2022 – 2028
Figure 5–64: United States Bexsero Market Value (Million US$),2018 – 2021
Figure 5–65: United States Bexsero Market Value Forecast (Million US$),2022 – 2028
Figure 5–66: United States Menveo Market Value (Million US$),2018 – 2021
Figure 5–67: United States Menveo Market Value Forecast (Million US$),2022 – 2028
Figure 5–68: United States Trumenba Market Value (Million US$),2018 – 2021
Figure 5–69: United States Trumenba Market Value Forecast (Million US$),2022 – 2028
Figure 5–70: United States Shingrix Market Value (Million US$),2018 – 2021
Figure 5–71: United States Shingrix Market Value Forecast (Million US$),2022 – 2028
Figure 5–72: United States Pentacel Market Value (Million US$),2018 – 2021
Figure 5–73: United States Pentacel Market Value Forecast (Million US$),2022 – 2028
Figure 5–74: United States Recombivax HB Market Value (Million US$),2018 – 2021
Figure 5–75: United States Recombivax HB Market Value Forecast (Million US$),2022 – 2028
Figure 5–76: United States Rotateq Market Value (Million US$),2018 – 2021
Figure 5–77: United States Rotateq Market Value Forecast (Million US$),2022 – 2028
Figure 5–78: United States Rotarix Market Value (Million US$),2018 – 2021
Figure 5–79: United States Rotarix Market Value Forecast (Million US$),2022 – 2028
Figure 5–80: United States Pediarix Market Value (Million US$),2018 – 2021
Figure 5–81: United States Pediarix Market Value Forecast (Million US$),2022 – 2028
Figure 5–82: United States Infanrix Market Value (Million US$),2018 – 2021
Figure 5–83: United States Infanrix Market Value Forecast (Million US$),2022 – 2028
Figure 5–84: United States Heplisav–B Market Value (Million US$),2018 – 2021
Figure 5–85: United States Heplisav–B Market Value Forecast (Million US$),2022 – 2028
Figure 5–86: United States TDVAX Market Value (Million US$),2018 – 2021
Figure 5–87: United States TDVAX Market Value Forecast (Million US$),2022 – 2028
Figure 5–88: United States BioThrax Market Value (Million US$),2018 – 2021
Figure 5–89: United States BioThrax Market Value Forecast (Million US$),2022 – 2028
Figure 5–90: United States Other Human Vaccines Market Value (Million US$),2018 – 2021
Figure 5–91: United States Other Human Vaccines Market Value Forecast (Million US$),2022 – 2028
